SE388849B - Forfarande for framstellning av nya aminer med beta-receptorstimulerande verkan - Google Patents

Forfarande for framstellning av nya aminer med beta-receptorstimulerande verkan

Info

Publication number
SE388849B
SE388849B SE7401958A SE7401958A SE388849B SE 388849 B SE388849 B SE 388849B SE 7401958 A SE7401958 A SE 7401958A SE 7401958 A SE7401958 A SE 7401958A SE 388849 B SE388849 B SE 388849B
Authority
SE
Sweden
Prior art keywords
procedure
preparation
beta receptor
receptor stimulating
stimulating effects
Prior art date
Application number
SE7401958A
Other languages
English (en)
Swedish (sv)
Other versions
SE7401958L (de
Inventor
E I Carlsson
N H A Persson
B R Samuelsson
K I L Wetterlin
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haessle Ab filed Critical Haessle Ab
Priority to SE7401958A priority Critical patent/SE388849B/xx
Priority to ZA00750381A priority patent/ZA75381B/xx
Priority to DE19752502993 priority patent/DE2502993A1/de
Priority to AT96475*#A priority patent/AT334881B/de
Priority to DD184143A priority patent/DD118614A5/xx
Priority to CH169075A priority patent/CH616648A5/de
Priority to FI750390A priority patent/FI62055B/fi
Priority to SU752104405A priority patent/SU603332A3/ru
Priority to AU78116/75A priority patent/AU497441B2/en
Priority to GB6172/75A priority patent/GB1492647A/en
Priority to IE279/75A priority patent/IE41350B1/xx
Priority to NO750468A priority patent/NO140628C/no
Priority to HUHE678A priority patent/HU169704B/hu
Priority to CA220,014A priority patent/CA1052387A/en
Priority to FR7504553A priority patent/FR2261000B1/fr
Priority to US05/549,841 priority patent/US4244969A/en
Priority to DK53975AA priority patent/DK135711B/da
Priority to LU71846A priority patent/LU71846A1/xx
Priority to CS75986A priority patent/CS202035B2/cs
Priority to NL7501785A priority patent/NL7501785A/xx
Priority to BE153340A priority patent/BE825515A/xx
Priority to JP50018088A priority patent/JPS50116433A/ja
Publication of SE7401958L publication Critical patent/SE7401958L/xx
Priority to SU762315654A priority patent/SU609460A3/ru
Priority to SU7602314963A priority patent/SU577971A3/ru
Priority to AT415076A priority patent/AT341498B/de
Priority to AT414976A priority patent/AT341497B/de
Publication of SE388849B publication Critical patent/SE388849B/xx
Priority to CS785579A priority patent/CS202036B2/cs
Priority to CS785580A priority patent/CS202037B2/cs
Priority to IT7950875A priority patent/IT7950875A0/it
Priority to US06/150,883 priority patent/US4336267A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/52—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE7401958A 1974-02-14 1974-02-14 Forfarande for framstellning av nya aminer med beta-receptorstimulerande verkan SE388849B (sv)

Priority Applications (30)

Application Number Priority Date Filing Date Title
SE7401958A SE388849B (sv) 1974-02-14 1974-02-14 Forfarande for framstellning av nya aminer med beta-receptorstimulerande verkan
ZA00750381A ZA75381B (en) 1974-02-14 1975-01-20 Heart active compounds
DE19752502993 DE2502993A1 (de) 1974-02-14 1975-01-25 Amine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
AT96475*#A AT334881B (de) 1974-02-14 1975-02-10 Verfahren zur herstellung neuer 1-phenoxy-2-hydroxy-3-aminopropane und deren saureadditionssalze
DD184143A DD118614A5 (de) 1974-02-14 1975-02-12
CH169075A CH616648A5 (de) 1974-02-14 1975-02-12
FI750390A FI62055B (fi) 1974-02-14 1975-02-12 Foerfarande foer framstaellning av aminer som stimulerar hjaertats beta-receptorer
SU752104405A SU603332A3 (ru) 1974-02-14 1975-02-12 Способ получени алканоламинов или их солей в виде рацемата или оптически-активных антиподов
AU78116/75A AU497441B2 (en) 1974-02-14 1975-02-12 Heart active compounds
US05/549,841 US4244969A (en) 1974-02-14 1975-02-13 Heart active compounds
IE279/75A IE41350B1 (en) 1974-02-14 1975-02-13 Substituted phenoxypropanolamines
NO750468A NO140628C (no) 1974-02-14 1975-02-13 Analogifremgangsmaate for fremstilling av nye, terapeutisk virksomme aminer
HUHE678A HU169704B (de) 1974-02-14 1975-02-13
CA220,014A CA1052387A (en) 1974-02-14 1975-02-13 Heart active compounds
FR7504553A FR2261000B1 (de) 1974-02-14 1975-02-13
GB6172/75A GB1492647A (en) 1974-02-14 1975-02-13 Substituted phenoxy propanolamines
NL7501785A NL7501785A (nl) 1974-02-14 1975-02-14 Werkwijze ter bereiding van verbindingen die de werking van het hart beinvloeden, aldus bereide verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
JP50018088A JPS50116433A (de) 1974-02-14 1975-02-14
LU71846A LU71846A1 (de) 1974-02-14 1975-02-14
CS75986A CS202035B2 (en) 1974-02-14 1975-02-14 Process for preparing new p-hydroxyphenoxypropanolamines
DK53975AA DK135711B (da) 1974-02-14 1975-02-14 Analogifremgangsmåde til fremstilling af hidtil ukendte, hjerteaktive substituerede fenoxyisopropanolaminer.
BE153340A BE825515A (fr) 1974-02-14 1975-02-14 Composes agissant sur le coeur
SU762315654A SU609460A3 (ru) 1974-02-14 1976-01-20 Способ получени производных аминопропанола или их солей
SU7602314963A SU577971A3 (ru) 1974-02-14 1976-01-23 Способ получени производных пропаноламина или их солей
AT414976A AT341497B (de) 1974-02-14 1976-06-08 Verfahren zur herstellung neuer 1-phenoxy-2-hydroxy-3-aminopropane und deren saureadditionssalze
AT415076A AT341498B (de) 1974-02-14 1976-06-08 Verfahren zur herstellung neuer 1-phenoxy-2-hydroxy-3-aminopropane und deren saureadditionssalze
CS785579A CS202036B2 (en) 1974-02-14 1978-08-28 Process for preparing new p-hydroxyphenoxypropanolamines
CS785580A CS202037B2 (en) 1974-02-14 1978-08-28 Process for preparing new p-hydroxyphenoxypropanolamines
IT7950875A IT7950875A0 (it) 1974-02-14 1979-11-21 Composti dotati di attivita' di stimolo dei beta-recettori cardiaci eprocedimento per la loro preparazione
US06/150,883 US4336267A (en) 1974-02-14 1980-05-19 Heart active compounds and methods of use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7401958A SE388849B (sv) 1974-02-14 1974-02-14 Forfarande for framstellning av nya aminer med beta-receptorstimulerande verkan

Publications (2)

Publication Number Publication Date
SE7401958L SE7401958L (de) 1975-08-15
SE388849B true SE388849B (sv) 1976-10-18

Family

ID=20320208

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7401958A SE388849B (sv) 1974-02-14 1974-02-14 Forfarande for framstellning av nya aminer med beta-receptorstimulerande verkan

Country Status (23)

Country Link
US (2) US4244969A (de)
JP (1) JPS50116433A (de)
AT (1) AT334881B (de)
AU (1) AU497441B2 (de)
BE (1) BE825515A (de)
CA (1) CA1052387A (de)
CH (1) CH616648A5 (de)
CS (2) CS202035B2 (de)
DD (1) DD118614A5 (de)
DE (1) DE2502993A1 (de)
DK (1) DK135711B (de)
FI (1) FI62055B (de)
FR (1) FR2261000B1 (de)
GB (1) GB1492647A (de)
HU (1) HU169704B (de)
IE (1) IE41350B1 (de)
IT (1) IT7950875A0 (de)
LU (1) LU71846A1 (de)
NL (1) NL7501785A (de)
NO (1) NO140628C (de)
SE (1) SE388849B (de)
SU (3) SU603332A3 (de)
ZA (1) ZA75381B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001161A (en) * 1984-01-10 1991-03-19 Aktiebolaget Hassle Pharmaceutical composition comprising metroprolol succinate

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210653A (en) * 1978-06-27 1980-07-01 Merck & Co., Inc. Pyridyloxypropanolamines
SE8004088L (sv) * 1980-06-02 1981-12-03 Haessle Ab Nya substituerade 3-fenoxi-l-alkoxikarbonylalkylamino-propanol-2-er med beta-receptorblockerande egenskaper samt forfarande for deras framstellning, farmaceutiska beredningar innehallande desamma och metod att ...
US4396629A (en) * 1980-12-29 1983-08-02 Sterling Drug Inc. Compositions, processes and method
CA1262729A (en) * 1983-10-19 1989-11-07 Leo Alig Phenoxypropanolamines
US5166218A (en) * 1983-10-19 1992-11-24 Hoffmann-La Roche Inc. Phenoxypropanolamines and pharmaceutical compositions thereof
DE3544172A1 (de) * 1985-12-13 1987-06-19 Lentia Gmbh Neue kristalline salze von aryloxy-propanolaminen, verfahren zu ihrer herstellung und ihre verwendung
ATE67480T1 (de) * 1987-03-26 1991-10-15 Helopharm Petrik Co Kg Verfahren zur herstellung von 5-hydroxydiprafenon und seiner salze mit saeuren.
IL126458A (en) * 1996-04-09 2004-06-20 Nps Pharma Inc Calcium receptor inhibiting calcilytic compounds
US6818660B2 (en) 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
US5966498A (en) * 1996-08-07 1999-10-12 Lakewood Engineering And Manufacturing Company End closure assembly for oil-filled heater
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
US7202261B2 (en) 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
JP4604583B2 (ja) * 2004-07-20 2011-01-05 ダイソー株式会社 １−アミド−３−（２−ヒドロキシフェノキシ）−２−プロパノール誘導体、ならびに２−アミドメチル−１，４−ベンゾジオキサン誘導体の製造法
IL165365A0 (en) 2004-11-24 2006-01-15 Q Core Ltd Finger-type peristaltic pump
JP4934287B2 (ja) * 2005-04-05 2012-05-16 花王株式会社 美白剤
FR2916441B1 (fr) * 2007-05-22 2009-08-28 Clariant Specialty Fine Chem Procede de racemisation d'alpha-aminoacetals optiquement actifs.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL301580A (de) * 1962-12-11
GB1069345A (en) * 1963-07-19 1967-05-17 Ici Ltd New alkanolamine derivatives
DE1922003C3 (de) * 1969-04-30 1979-10-11 Boehringer Mannheim Gmbh, 6800 Mannheim N-(3-Aryloxy-2-hydroxypropyl)-aminocarbonsäuren, deren Ester, Amide und Salze, Verfahren zur Herstellung dieser Verbindungen und deren Verwendung bei der Bekämpfung von Herzinsuffizienz
BE790165A (fr) * 1971-12-14 1973-02-15 Parke Davis & Co Nouveaux aminoalcanols et procede pour les preparer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001161A (en) * 1984-01-10 1991-03-19 Aktiebolaget Hassle Pharmaceutical composition comprising metroprolol succinate

Also Published As

Publication number Publication date
FI750390A (de) 1975-08-15
AU497441B2 (en) 1978-12-14
SU577971A3 (ru) 1977-10-25
BE825515A (fr) 1975-08-14
GB1492647A (en) 1977-11-23
NO140628B (no) 1979-07-02
DD118614A5 (de) 1976-03-12
HU169704B (de) 1977-02-28
FR2261000A1 (de) 1975-09-12
DK53975A (de) 1975-10-06
US4336267A (en) 1982-06-22
ATA96475A (de) 1976-06-15
DE2502993A1 (de) 1975-09-04
IE41350L (en) 1975-08-14
AU7811675A (en) 1976-08-12
NL7501785A (nl) 1975-08-18
CA1052387A (en) 1979-04-10
IT7950875A0 (it) 1979-11-21
LU71846A1 (de) 1975-12-09
FR2261000B1 (de) 1978-07-21
SU603332A3 (ru) 1978-04-15
SE7401958L (de) 1975-08-15
CS202035B2 (en) 1980-12-31
US4244969A (en) 1981-01-13
IE41350B1 (en) 1979-12-19
JPS50116433A (de) 1975-09-11
CS202036B2 (en) 1980-12-31
NO750468L (de) 1975-08-15
ZA75381B (en) 1976-01-28
DK135711B (da) 1977-06-13
SU609460A3 (ru) 1978-05-30
NO140628C (no) 1979-10-10
FI62055B (fi) 1982-07-30
DK135711C (de) 1977-11-21
CH616648A5 (de) 1980-04-15
AT334881B (de) 1977-02-10

Similar Documents

Publication Publication Date Title
SE424637B (sv) Analogiforfarande for framstellning av pyridylguanidiner med terapeutisk verkan
SE388849B (sv) Forfarande for framstellning av nya aminer med beta-receptorstimulerande verkan
SE412906B (sv) Forfarande for framstellning av 3-aryloxi-3-fenylpropylaminer med farmakologisk verkan
SE420921B (sv) Analogiforfarande for framstellning av kinazolinderivat med terapeutisk verkan
SE384853B (sv) Forfarande for framstellning av nya aminer
SE429338B (sv) Forfarande for framstellning av substituerade 2-bensylpyrrolidiner med terapeutisk verkan
SE414633B (sv) Forfarande for framstellning av nya 4-(3-tert butylamino-propoxi)-2-metyl-indolderivat med terapeutisk verkan
SE410596B (sv) Analogiforfarande for framstellning av bensoyl-fenylalanyl-tyrosinderivat med terapeutisk verkan
SE406763B (sv) Forfarande for framstellning av nya imidazoliner med antihypertensiv verkan
SE7600343L (sv) Forfarande for framstellning av ferrocenderivat med terapeutisk verkan
SE7703721L (sv) Forfarande for framstellning av hexahydroprimidinforeningar med terapeutisk verkan
SE421917B (sv) Analogiforfarande for framstellning av nya derivat av 2-metyl-1-indolyl-ettikssyra med terapeutisk verkan
SE7608538L (sv) Forfarande for framstellning av substituerade fenylalkylaminoalkylbensenderivat med terapeutisk verkan
SE7510833L (sv) Forfarande for framstellning av nya cefalosporinderivat
SE7608115L (sv) Forfarande for framstellning av kinoxalinderivat med terapeutisk verkan
SE394429B (sv) Forfarande for framstellning av aminopyrrolderivat med terapeutisk verkan
SE389108B (sv) Forfarande for framstellning av cyklopropylfenylpyrrolidinderivat med farmakologisk verkan
SE426831B (sv) Vinyldimetylsilylmetoxiderivat till anvendning for framstellning av sasom mellanprodukter anvendbara omettade disilaner
SE409113B (sv) Foerfarande foer framstaellning av nya derivat av n-amino-3-fenylindoler med terapeutiska egenskaper
SE420835B (sv) Forfarande for framstellning av monokromonkarboxylsyror med terapentisk verkan
SE395689B (sv) Forfarande for framstellning av vissa angivna bensalacetonamidinohydrazonderivat med antiviral verkan
SE426946B (sv) Forfarande for framstellning av tioxanten-9-yliden-piperidinderivat med antipsykotisk verkan
SE7712219L (sv) Forfarande for framstellning av trans-5a-aryl-dekahydrobenzazpiner med terapeutisk verkan
SE7507566L (sv) Forfarande for framstellning av etylbensenderivat med terapeutisk verkan
SE427030B (sv) Forfarande for framstellning av bensofenonderivat med antikonvulsiv verkan